- Home
- TRDA vs ERAS Comparison
TRDA vs ERAS Comparison
Compare TRDA & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRDA
- ERAS
- Stock Information
- Founded
- TRDA 2016
- ERAS 2018
- Country
- TRDA United States
- ERAS United States
- Employees
- TRDA N/A
- ERAS N/A
- Industry
- TRDA Biotechnology: Pharmaceutical Preparations
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- TRDA Health Care
- ERAS Health Care
- Exchange
- TRDA Nasdaq
- ERAS Nasdaq
- Market Cap
- TRDA 301.0M
- ERAS 348.4M
- IPO Year
- TRDA 2021
- ERAS 2021
- Fundamental
- Price
- TRDA $7.50
- ERAS $1.54
- Analyst Decision
- TRDA Strong Buy
- ERAS Strong Buy
- Analyst Count
- TRDA 3
- ERAS 6
- Target Price
- TRDA $25.67
- ERAS $4.83
- AVG Volume (30 Days)
- TRDA 135.4K
- ERAS 1.2M
- Earning Date
- TRDA 08-12-2025
- ERAS 08-11-2025
- Dividend Yield
- TRDA N/A
- ERAS N/A
- EPS Growth
- TRDA N/A
- ERAS N/A
- EPS
- TRDA 0.61
- ERAS N/A
- Revenue
- TRDA $172,220,000.00
- ERAS N/A
- Revenue This Year
- TRDA N/A
- ERAS N/A
- Revenue Next Year
- TRDA N/A
- ERAS N/A
- P/E Ratio
- TRDA $11.75
- ERAS N/A
- Revenue Growth
- TRDA 5.74
- ERAS N/A
- 52 Week Low
- TRDA $6.59
- ERAS $1.01
- 52 Week High
- TRDA $21.79
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- TRDA 48.11
- ERAS 58.61
- Support Level
- TRDA $6.87
- ERAS $1.38
- Resistance Level
- TRDA $7.41
- ERAS $1.49
- Average True Range (ATR)
- TRDA 0.30
- ERAS 0.11
- MACD
- TRDA 0.05
- ERAS 0.01
- Stochastic Oscillator
- TRDA 90.30
- ERAS 96.97
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.